Kayexalate in Hyperkalemia – to give or not to give?

    NextPrevious

    Kayexalate in Hyperkalemia – to give or not to give?

    When a patient presents with hyperkalemia, in addition to the initial steps of obtaining an EKG and treating with calcium, insulin, glucose, albuterol, and furosemide if indicated, consultants will often ask us to also administer sodium polystyrene sulfonate, more commonly known as kayexalate, pending hemodialysis. Is this management strategy supported by evidence? Reviewing the (rather sparse) literature, the short answer appears to be no.

     

    Kayexalate was approved for use in 1958, four years before the FDA began requiring drug manufacturers to demonstrate efficacy as well as safety. It theoretically lowers potassium by binding cations in the GI tract and increasing GI excretion of potassium. In the best case scenario, it takes on the order of hours to begin to have an effect. Moreover, it may not have any acute effect at all; some studies have demonstrated that, when taken for multiple days, kayexalate can effectively treat mild hyperkalemia in the outpatient setting, but there is almost no data supporting the use of kayexalate in moderate or severe hyperkalemia. One study found that a single dose of kayexalate + laxative (phenolphthalein or sorbitol) given to ESRD patients did not increase stool potassium output over a 12 hour period compared to administering a laxative alone. It did not lower serum potassium by a significant amount either, though these patients were not hyperkalemic to start with.

    There have also been numerous case reports of intestinal ischemia/necrosis, bezoar formation, and death associated with kayexalate, particularly when administered with sorbitol. Furthermore, because it is a general cation binder, it may decrease absorption of other medications such as lithium and thyroxine.

    Patiromer is another recently FDA-approved gastrointestinal cation binders that have a higher selectivity for binding potassium than kayexalate, though again there is as yet no data on its efficacy in acute hyperkalemia. It also is not currently available at Sinai. ZS-9 is another similar drug in the pipeline, but it’s not yet been FDA approved.

     

    Therefore, the next time the consulting or admitting team raises the question of giving kayexalate as an adjunctive therapy for hyperkalemia, consider bringing up its potential for significant harm and the paucity of data on its efficacy in acute hyperkalemia. If the patient is unable excrete potassium effectively through lasix, perhaps it is time for hemodialysis.

     

    Special thanks to Dr. Gregory Fernandez for prompting the review of this topic.

     

    References:

    J Am Soc Nephrol. 2010 May;21(5):733-5. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective?

    J Am Soc Nephrol. 1998 Oct. Effect of Single Dose Resin-Cathartic Therapy on Serum Potassium Concentration in Patients with End-Stage Renal Disease.

    Clin J Am Soc Nephrol. 2015 Dec 7;10(12):2136-42. Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD.

    Pharmacy and Therapeutics. 41(1), 43–50. Potassium-Binding Agents for the Clinical Management of Hyperkalemia.

    Food and Drug Administration. 2009. Kayexalate

    Emcrit – Is Kayexalate Useless?

    • Welcome! This is the website for the Mount Sinai Emergency Ultrasound Division. It serves as an information resource for residents, fellows, medical students and others seeking information about point-of-care ultrasound. There is a lot ofRead more

    • renal handling of water

      If you were on a tea & toast diet, how much water would you need to drink before you develop hyponatremia? I haven’t seen anyone work out the numbers before so here are my calculations. AndRead more

    • acute acidemia physiology

      As alluded to in the first post, don’t be fooled by a “normal” potassium in the setting of DKA because osmotic diuresis and H+/K+ exchange means that total body potassium is actually LOW. You all knowRead more

    • renal handling of potassium

      the first symptom of hyperkalemia is death Earlier post covered temporizing measures to counter hyperkalemia — namely, intracellular shift, increasing cardiac myocyte threshold potential. Give furosemide if the patient still urinates and consider dialysis, but then askRead more

    • bicarbonate revisited

      Previous post reviewed the safety of balanced crystalloids in hyper K. But what was up with serum bicarbonate decreasing with saline administration? This post introduces a new way of looking at the anion gap to possiblyRead more

    • hyperkalemia and balanced crystalloids

      Is it safe to give LR or plasmalyte to a hyperkalemic patient (these balanced crystalloids have 4-5 mEq/L K as opposed to 0 mEq/L K in normal saline)? Postponing the discussion of renal handling of potassium toRead more

    • hyperkalemia physiology

      You’ll likely encounter hyperkalemia on your next Resus / Cardiac shift, and you’ll instinctively treat it. But take a moment to review the fascinating physiology behind the “cocktail”! First, consider how K+ is buffered byRead more

    • Slow down your tachycardia (but not really)

      You’re sitting in resus bemoaning the departure of your most beloved attending when suddenly a patient wheels in without warning. The patient looks relatively stable but the triage RN tells you her heart rate wasRead more

    • Otitis externa: use the ear wick!

      Acute otitis externa (AOE) is a common complaint seen in pediatric as well as adult emergency departments. AOE is typically not accompanied by acute otitis media, although concurrent cases are possible. Also called “swimmer’s ear”Read more

    NextPrevious